Future progress will require: (1) Parameter optimization studies: Systematic in vitro screening of DECLARATIONS Authors contribution Writing - original draft, investigation, conceptualization, and funding acquisition: Wang LY Writing - review and editing: Fan MY, Jiang XY, Bing KJ, Wang YJ, Zhang H Writing - review and editing, supervision: Wang KS, Huang YM Availability of data and materials Not applicable
Cardiology in Review, 32(1), 8390
Timelines reported below come from per-compound Phase 2/3 trials, the closest-analog REDEFINE 1 cagrilintide+semaglutide trial, and self-organized community protocols
Fourth, we leverage our experience across hundreds of injection clients